DK3354267T3 - Stabiliseret sulforaphan - Google Patents

Stabiliseret sulforaphan Download PDF

Info

Publication number
DK3354267T3
DK3354267T3 DK18162130.1T DK18162130T DK3354267T3 DK 3354267 T3 DK3354267 T3 DK 3354267T3 DK 18162130 T DK18162130 T DK 18162130T DK 3354267 T3 DK3354267 T3 DK 3354267T3
Authority
DK
Denmark
Prior art keywords
sulforaphan
stabilized
Prior art date
Application number
DK18162130.1T
Other languages
English (en)
Inventor
Ido Dov Dagan
Albert Roger Frisbee
Peter Wyatt Newsome
Michel Pierre Baudet
Original Assignee
Pharmagra Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US88187507P priority Critical
Application filed by Pharmagra Labs Inc filed Critical Pharmagra Labs Inc
Priority to EP14166888.9A priority patent/EP2796140B1/en
Application granted granted Critical
Publication of DK3354267T3 publication Critical patent/DK3354267T3/da
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39641899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3354267(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16Isothiocyanates
    • C07C331/18Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms
    • C07C331/20Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16Isothiocyanates
    • C07C331/26Isothiocyanates having isothiocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/025Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
DK18162130.1T 2007-01-23 2008-01-23 Stabiliseret sulforaphan DK3354267T3 (da)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US88187507P true 2007-01-23 2007-01-23
EP14166888.9A EP2796140B1 (en) 2007-01-23 2008-01-23 Stabilized Sulforaphane

Publications (1)

Publication Number Publication Date
DK3354267T3 true DK3354267T3 (da) 2019-08-26

Family

ID=39641899

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14166888.9T DK2796140T3 (da) 2007-01-23 2008-01-23 Stabiliseret sulforaphan
DK18162130.1T DK3354267T3 (da) 2007-01-23 2008-01-23 Stabiliseret sulforaphan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14166888.9T DK2796140T3 (da) 2007-01-23 2008-01-23 Stabiliseret sulforaphan

Country Status (16)

Country Link
US (1) US7879822B2 (da)
EP (4) EP2120969A4 (da)
JP (4) JP2010516766A (da)
AU (1) AU2008209543B2 (da)
CA (1) CA2672971C (da)
DK (2) DK2796140T3 (da)
ES (2) ES2743043T3 (da)
HK (1) HK1199407A1 (da)
HR (1) HRP20191495T1 (da)
HU (2) HUE046151T2 (da)
LT (1) LT3354267T (da)
PL (2) PL3354267T3 (da)
PT (1) PT3354267T (da)
SI (1) SI3354267T1 (da)
TR (1) TR201808561T4 (da)
WO (1) WO2008091608A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046151T2 (hu) * 2007-01-23 2020-02-28 Pharmagra Labs Inc Stabilizált szulforafán
WO2010065329A2 (en) * 2008-11-25 2010-06-10 The Board Of Regents Of The University Of Texas System Nanoparticles for cancer treatment
BE1019434A3 (fr) * 2010-07-23 2012-07-03 Auriga Internat Stabilisation du sulforaphane.
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
ES2425294B1 (es) * 2012-03-09 2014-09-02 Consejo Superior De Investigaciones Científicas (Csic) Compuestos derivados de sulforafano, método de obtención y su uso médico, alimenticio y cosmético
CN102697764A (zh) * 2012-05-03 2012-10-03 苏州纳晶医药技术有限公司 一种含有异硫氰酸苯乙酯的肠溶固体制剂
WO2013179056A1 (en) * 2012-06-01 2013-12-05 Pharmagra Labs, Inc. Sulforaphane isolation and purification
US9567405B2 (en) * 2012-06-01 2017-02-14 Pharmagra Labs, Inc. Method of synthesising sulforaphane
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
DE102014012367B3 (de) * 2014-08-25 2015-08-27 De Smaakmaker Holding B. V. Method for determining the concentration of glucoraphanin and / or sulforaphane in a plant
CN111902046A (zh) * 2018-02-02 2020-11-06 联邦科学技术研究组织 保护生物活性物和/或其前体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669984A (en) * 1900-02-06 1901-03-19 Josef Federmann Spittoon.
US673744A (en) * 1900-08-06 1901-05-07 Pearl M Westerfield Vending-box.
US5458903A (en) * 1993-01-19 1995-10-17 The Pillsbury Company High fat biscuit mix and products resulting therefrom
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
JP3604172B2 (ja) * 1994-03-22 2004-12-22 株式会社白元 除菌組成物、及び除菌方法
US5589504A (en) 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
US6117429A (en) 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
FR2776666B1 (fr) * 1998-03-31 2002-09-06 Commissariat Energie Atomique INCLUSION COMPLEXES IN ORGANIC ISOTHIOCYANATE CYCLODEXTRINS, IN PARTICULAR BACTERIOSTATICS, BACTERICIDES AND / OR FUNGICIDES OR THEIR NATURAL PRECURSORS, AND THEIR PREPARATION
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
DE60004768T2 (de) 1999-07-01 2004-07-08 Italfarmaco S.P.A. COMPLEXES OF PAROXETINE WITH CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVES
US6361812B1 (en) 1999-11-18 2002-03-26 The Procter & Gamble Co. Products comprising an isothiocyanate preservative system and methods of their use
JP2003518033A (ja) * 1999-12-20 2003-06-03 コグニス・フランス・ソシエテ・アノニム 化粧品製剤および/または医薬製剤
US6433011B1 (en) 2000-03-08 2002-08-13 American Health Foundation Method for inhibiting formation of aberrant crypt foci in the colon of a mammal
JP2002051732A (ja) 2000-06-12 2002-02-19 Access Business Group Llc Compositions and methods for correcting dietary phytochemical deficiencies
US6812248B2 (en) 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
CN100522154C (zh) 2000-08-21 2009-08-05 杰德W·费伊 异硫氰酸酯类化合物在制备治疗螺杆菌感染的药物中的用途
JP2002187842A (ja) * 2000-12-19 2002-07-05 Toyo Shinyaku:Kk ケール加工品およびその加工方法
JP2003146803A (ja) * 2001-11-13 2003-05-21 Carex Inc 抗菌性粉末組成物およびその製造方法
WO2006105196A2 (en) * 2005-03-28 2006-10-05 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
FR2888235B1 (fr) 2005-07-07 2007-09-14 Nutrinov Sa Procede d'extraction de sulforaphane a partir de broyat de crucifere contenant de la glucoraphanine
CN101120948A (zh) * 2006-08-08 2008-02-13 普文英 一种具有化学保护、癌症预防和治疗用途的化合物组合物
HUE046151T2 (hu) * 2007-01-23 2020-02-28 Pharmagra Labs Inc Stabilizált szulforafán

Also Published As

Publication number Publication date
AU2008209543B2 (en) 2014-03-13
HUE046151T2 (hu) 2020-02-28
JP2010516766A (ja) 2010-05-20
CA2672971A1 (en) 2008-07-31
JP2014055140A (ja) 2014-03-27
HUE039549T2 (hu) 2019-01-28
PL2796140T3 (pl) 2018-09-28
US20080176942A1 (en) 2008-07-24
SI3354267T1 (sl) 2019-11-29
EP2532352A1 (en) 2012-12-12
JP2016145218A (ja) 2016-08-12
JP6566886B2 (ja) 2019-08-28
AU2008209543A1 (en) 2008-07-31
EP2120969A4 (en) 2010-06-02
HK1199407A1 (zh) 2015-07-03
ES2674052T3 (es) 2018-06-27
ES2743043T3 (es) 2020-02-18
EP3354267A1 (en) 2018-08-01
US7879822B2 (en) 2011-02-01
PT3354267T (pt) 2019-09-10
EP2796140A3 (en) 2014-12-24
EP2120969A1 (en) 2009-11-25
JP2018027956A (ja) 2018-02-22
DK2796140T3 (da) 2018-06-25
WO2008091608A1 (en) 2008-07-31
EP2796140B1 (en) 2018-05-02
EP2796140A2 (en) 2014-10-29
PL3354267T3 (pl) 2019-11-29
TR201808561T4 (tr) 2018-07-23
CA2672971C (en) 2014-03-11
HRP20191495T1 (hr) 2019-11-29
JP6677688B2 (ja) 2020-04-08
LT3354267T (lt) 2019-09-25
EP3354267B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
LU92600I2 (en) Sovaldi (sofosbuvir)
DK2209856T3 (da) Aerogelsammensætninger
DK2665193T3 (da) Styrekanalallokering
DK2205737T3 (da) Mikromirer
DK2158214T3 (da) Glukagonanaloger
DK2345653T3 (da) Morphinanforbindelser
DK2170321T3 (da) Ormekur-kombination
DK2121534T3 (da) Enkeltrudelaminater
DK2124668T3 (da) Hårplejeindretning
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
AT540954T (de) Aminoheterocyclische verbindungen
AT525702T (de) Erweiterte widgetarchitektur
DK2195058T3 (da) Laryngealmaske
DK2481796T3 (da) Glucoamylasevarianter
DK2203551T3 (da) Bifidobakterieart
AT531723T (de) Steviolglycosidisomere
BRPI0817238A2 (pt) Transconector
AT511375T (de) Getränkeaufbrüheinheit
AT513978T (de) Drehsteuervorrichtungsandockstation
AT512633T (de) Wirbelsäulen-verbindungselement
AT544742T (de) Insektizide arylpyrrolidine
BRPI0814563A2 (pt) Nanosuperfície
AT530279T (de) Tangentialschneideeinsatz
DK2514750T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner